Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and Abiraterone in Oligo-metastatic Prostate Cancer
NCT06198387Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of abiraterone in prostate cancer (PCa), sponsored by Changhai Hospital. Primary endpoint: Progression-Free Survival 2 at 3 years. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06198387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06198387.